Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13010704 | 0.91 | KDM4E (0.40) | SMN1; SMN2HSD11B1OPRM1OPRL1KMT2A | |
| SCHEMBL22737188 | 0.89 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD11B1OPRM1OPRL1KDM4E | |
| SCHEMBL19214879 | 0.88 | KDM4E (0.41) | SMN1; SMN2HSD11B1OPRM1OPRL1KMT2A | |
| SCHEMBL24833174 | 0.87 | OPRL1 (0.49) | OPRM1OPRL1KMT2A | |
| SCHEMBL27346203 | 0.86 | KDM4E (0.40) | SMN1; SMN2HSD11B1OPRM1OPRL1KMT2A | |
| SCHEMBL15837587 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2OPRM1OPRL1 | |
| SCHEMBL4762401 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2OPRM1OPRL1 | |
| SCHEMBL18664106 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2OPRM1OPRL1 | |
| SCHEMBL25075207 | 0.84 | GNAI3 (0.38) | KDM4E | |
| SCHEMBL13185791 | 0.83 | SMN1; SMN2 (0.37) | SMN1; SMN2HSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070583-A2 | THROMBOPOIETIN MIMETICS | STATEGICS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7309757-B2 | Polymers for the delivery of bioactive agents and methods of their preparation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-12-18 | — | — | US | disclosed |
| US-7285565-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009613-A1 | Methods and compositions for determining the sequence of nucleic acid molecules | CPSF6, RNMT, POLM | SMN1; SMN2 936/4885HSD11B1 4766/4885OPRM1 1617/4885 |
| US-20080139621-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | SMN1; SMN2 1872/4885HSD11B1 4816/4885OPRM1 1787/4885 |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | FAAH, FAAH2, EPHX2 | SMN1; SMN2 4514/4885HSD11B1 346/4885OPRM1 2377/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | SMN1; SMN2 3253/4885HSD11B1 2723/4885OPRM1 3220/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | SMN1; SMN2 524/4885HSD11B1 745/4885OPRM1 4106/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | SMN1; SMN2 2604/4885HSD11B1 2940/4885OPRM1 4583/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | SMN1; SMN2 464/4885HSD11B1 4671/4885OPRM1 3114/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | SMN1; SMN2 1048/4885HSD11B1 3735/4885OPRM1 4446/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | SMN1; SMN2 3253/4885HSD11B1 2723/4885OPRM1 3220/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | SMN1; SMN2 368/4885HSD11B1 3744/4885OPRM1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.